China Experts See Rising Drug Prices Jeopardizing Health System
This article was originally published in PharmAsia News
Experts on China report the country's health care system is in jeopardy because of soaring medical costs, including the price of drugs, which have gone unchecked for two decades. A report in the journal The Lancet attributed some of the costs to the price of medicines and treatments that in turn have caused hospitals to raise their prices to the point hospitalization can cost the annual income of some Chinese. The experts traced the rising costs faced by patients to a decline in state support for hospitals and doctors. (Click here for more
You may also be interested in...
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The International Medical Device Regulators Forum, perhaps most notorious for its efforts to standardize audit processes between nations with its Medical Device Single Audit Program, is also focusing on harmonizing device reviews and adverse event codes.
Dr Reddy’s Laboratories has become the third Revlimid ANDA sponsor to settle patent litigation action with Bristol Myers Squibb’s Celgene. However, the Indian company will join Alvogen in not being able to launch before first settler Natco, which has partnered with Teva’s Watson.